Unspecified B-cell lymphoma, lymph nodes of multiple sites is a type of non-Hodgkin lymphoma characterized by the proliferation of B-lymphocytes in lymph nodes across multiple anatomical sites. This condition is clinically significant due to its potential for aggressive behavior and varied treatment responses. Accurate coding with ICD-10 Code C85.18 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that healthcare providers can effectively track and manage patient outcomes.
ICD-10 Code C85.18 represents Unspecified B-cell lymphoma, lymph nodes of multiple sites, indicating a diagnosis of lymphoma affecting multiple lymph node regions without specific subtype classification. This code is used when the precise type of B-cell lymphoma is not determined, and it is crucial for clinical documentation and billing purposes, particularly in oncology settings.
Unspecified B-cell lymphoma, lymph nodes of multiple sites, is a hematological malignancy that arises from B-lymphocytes, leading to lymphadenopathy and potential systemic symptoms. The etiology may involve genetic mutations, environmental factors, or immune dysregulation. Prompt diagnosis and treatment are critical due to the risk of disease progression.
ICD-10 Code C85.18 is utilized in SOAP notes to document the presence of unspecified B-cell lymphoma affecting multiple lymph nodes. It plays a vital role in capturing patient symptoms, assessments, and treatment plans, ensuring comprehensive documentation in both acute and chronic care settings.
In SOAP notes, ICD-10 Code C85.18 connects subjective patient reports and objective clinical findings to a formal diagnosis of unspecified B-cell lymphoma. This code is essential for maintaining continuity of care, supporting accurate billing, and meeting EHR documentation standards.
The management of unspecified B-cell lymphoma, lymph nodes of multiple sites, often necessitates hospitalization for comprehensive evaluation and treatment. Therapeutic approaches may include chemotherapy, targeted therapy, or immunotherapy.


HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.
Learn moreICD-10 Code C85.18 is critical in medical billing, particularly in hospital, ER, or infectious disease care settings.
| CPT Code | Description |
|---|---|
| 96413 | Chemotherapy administration, intravenous, push technique, single or initial substance. |
| 85025 | Complete blood count (CBC) with automated differential white blood cell count. |
| 77014 | Radiologic examination, lymphatic system, including lymphangiography. |
| 99223 | Initial hospital care, typically 70 minutes or more of total time on the date of the encounter. |
Common Questions About Using ICD-10 Code C85.18 for Unspecified B-cell lymphoma, lymph nodes of multiple sites
What are the common symptoms of unspecified B-cell lymphoma?
Common symptoms include swollen lymph nodes, unexplained weight loss, fever, and night sweats. Patients may also experience fatigue and itching. These symptoms can vary based on the extent of the disease.
How is unspecified B-cell lymphoma diagnosed?
Diagnosis typically involves a combination of physical examination, imaging studies, and biopsy of affected lymph nodes. Histological analysis is crucial for confirming the diagnosis and determining the specific type of lymphoma.
What treatment options are available for unspecified B-cell lymphoma?
Treatment options may include chemotherapy, targeted therapy, and immunotherapy. The choice of treatment depends on the stage of the disease, patient health, and specific lymphoma characteristics.
Is hospitalization required for patients with unspecified B-cell lymphoma?
Hospitalization may be necessary for initial treatment, especially for chemotherapy administration or management of complications. Continuous monitoring is essential to address any adverse effects or disease progression.
Clinical Notes
SOAP notes
DAP notes
AI medical notes